Statistiche di base
| CIK | 1665988 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Bioventus Inc.
SEC Filings (Chronological Order)
Questa pagina fornisce un elenco completo e cronologico dei depositi SEC, esclusi i documenti di proprietà che forniamo altrove.
| August 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2025 Bioventus Inc. (Exact name of registrant as specified in charter) Delaware 001-37844 81-0980861 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| August 6, 2025 |
‘ m UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 28, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37844 BIOVEN |
|
| August 6, 2025 |
Bioventus Reports Second Quarter Financial Results Exhibit 99.1 Bioventus Reports Second Quarter Financial Results •Q2 reported revenue of $147.7 million declined 2.4%; Organic* revenue advanced 6.2% •Second quarter diluted earnings per share was $0.11 compared to a diluted loss per share of $0.40 in the prior-year period •Non-GAAP earnings* of $0.21 per share increased 31% •Cash from operations of $25.9 million increased 71% •Company reiterated r |
|
| August 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 31, 2025 Bioventus Inc. (Exact name of registrant as specified in charter) Delaware 001-37844 81-0980861 (State or other jurisdiction of incorporation) (Commission File Number) ( |
|
| August 4, 2025 |
EX-10.1 Exhibit 10.1 EXECUTION VERSION $400,000,000 CREDIT AGREEMENT dated as of July 31, 2025, by and among BIOVENTUS LLC, as Borrower, the Lenders referred to herein, as Lenders, and WELLS FARGO BANK, NATIONAL ASSOCIATION, as Administrative Agent, Swingline Lender and Issuing Lender WELLS FARGO SECURITIES, LLC, DNB MARKETS, INC., JPMORGAN CHASE BANK, N.A. and TRUIST SECURITIES, INC., as Joint Le |
|
| July 31, 2025 |
Exhibit 99.1 Bioventus Receives FDA 510(k) Clearances for two Next-Generation Peripheral Nerve Stimulation Products July 30, 2025 DURHAM, N.C., July 30, 2025 (GLOBE NEWSWIRE) - Bioventus Inc. (Nasdaq: BVS), a global leader in innovations for active healing, announced today a significant milestone with the U.S. Food and Drug Administration (FDA) 510(k) clearances for both TalisMann™ and StimTrial™, |
|
| July 31, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 30, 2025 Bioventus Inc. (Exact name of registrant as specified in charter) Delaware 001-37844 81-0980861 (State or other jurisdiction of incorporation) (Commission File Number) ( |
|
| June 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 3, 2025 Bioventus Inc. (Exact name of registrant as specified in charter) Delaware 001-37844 81-0980861 (State or other jurisdiction of incorporation) (Commission File Number) (I |
|
| June 2, 2025 |
Conflict Minerals Report as required by Items 1.01 and 1.02 of this Form Exhibit 1.01 Conflict Minerals Report Bioventus Inc. - For Year Ending December 31, 2024 This is the Conflict Minerals Report (“Report”) of Bioventus Inc. (herein referred to as “Bioventus,” the “Company,” “we,” “us,” or “our”). The information includes the activities of our consolidated subsidiaries, including Bioventus LLC. This Report is for calendar year 2024 and was prepared by Bioventus mana |
|
| June 2, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT Bioventus Inc. (Exact name of registrant as specified in charter) Delaware 001-37844 81-0980861 (State or other jurisdiction of incorporation or organization) (Commission File Number) (IRS Employer Identification Number) 4721 Emperor Boulevard, Suite 100, Durham, North Carolina 27703 (Addr |
|
| May 6, 2025 |
Bioventus Reports First Quarter Financial Results Exhibit 99.1 Bioventus Reports First Quarter Financial Results •Q1 reported revenue of $123.9 million declined 4.3%; Organic* revenue advanced 5.0% •First quarter net loss was $0.04 per share compared to a loss of $0.08 in the prior-year period •Non-GAAP earnings* of $0.08 per share increased 33% •Company reiterated revenue, Adjusted EBITDA* and Non-GAAP EPS* guidance for full year 2025 DURHAM, NC |
|
| May 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2025 Bioventus Inc. (Exact name of registrant as specified in charter) Delaware 001-37844 81-0980861 (State or other jurisdiction of incorporation) (Commission File Number) (IR |
|
| May 6, 2025 |
‘ m UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 29, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37844 BIOVE |
|
| April 22, 2025 |
BV1891 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37844 BIOVENT |
|
| April 22, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| April 22, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| March 11, 2025 |
Exhibit 10.20(a) LEASE AMENDMENT THIS LEASE AMENDMENT (the "Amendment") is dated as of October 14, 2024, by and between 7101 GOODLETT FARMS PARKWAY, LLC, a Tennessee limited liability company ("Landlord") and BIOVENTUS LLC, a Delaware limited liability company ("Tenant"). RECITALS: A. Landlord and Tenant executed that certain Lease dated November 17, 2021 (the "Lease") whereby Tenant leased from L |
|
| March 11, 2025 |
Exhibit 107.1 Calculation of Filing Fee Tables Form S-8 (Form Type) Bioventus Inc. (Exact Name of Registrant as Specified in its Charter) Table 1—Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount to be Registered (1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Class A common stock, $0. |
|
| March 11, 2025 |
Bioventus Announces Fourth Quarter and Full Year 2024 Financial Results Exhibit 99.1 Bioventus Announces Fourth Quarter and Full Year 2024 Financial Results •Accelerated fourth quarter sales growth to 13.5% •Fourth quarter gross margin expanded 310 bps and adjusted gross margin* expanded 230 bps •Fourth quarter cash from operations of $19.3 million increased 86.3% •Provides full-year 2025 financial guidance reflecting continued above market revenue growth and continue |
|
| March 11, 2025 |
Form of Bioventus Performance Restricted Stock Unit Award Grant Notice and Agreement Exhibit 10.16 BIOVENTUS, INC. 2021 EQUITY INCENTIVE PLAN PERFORMANCE RESTRICTED STOCK UNIT AWARD GRANT NOTICE Bioventus, Inc., a Delaware corporation (the “Company”), pursuant to its 2021 Equity Incentive Plan, as amended from time to time (the “Plan”), hereby grants to the individual listed below (“Participant”) the number of Performance Restricted Stock Units set forth below (the “PRSUs”). The P |
|
| March 11, 2025 |
Bioventus Inc. Insider Trading Policy, dated as of February 10, 2021 Exhibit 19.1 Bioventus Inc. Insider Trading Compliance Policy (As of February 10, 2021) This Insider Trading Compliance Policy (this “Policy”) of Bioventus Inc. (the “Company”) consists of seven sections: •Section I provides an overview; •Section II sets forth the policies of the Company prohibiting insider trading; •Section III explains insider trading; •Section IV consists of procedures that hav |
|
| March 11, 2025 |
List of patents and pending patent applications directed to Bioventus Inc.’s material products Bioventus Inc. Patent Listing Country Application Number Filing Date Patent Number Application Status Expected Expiration Date Description Product AU 2009324417 December 13, 2009 2009324417 Issued December 2029 Directed to methods of making osteoinductive implants OsteoAMP AU 2014259553 November 14, 2014 2014259553 Issued December 2029 Directed to methods of making osteoinductive implants OsteoAMP |
|
| March 11, 2025 |
As filed with the Securities and Exchange Commission on March 11, 2025 As filed with the Securities and Exchange Commission on March 11, 2025 Registration No. |
|
| March 11, 2025 |
Exhibit 21.1 Legal Name Jurisdiction of Incorporation Bioventus Inc. Delaware Bioventus LLC Delaware Bioventus Holdings LLC (1) North Carolina Bioventus Coöperatief U.A.(2) The Netherlands Bioventus Canada, Ulc (3) British Columbia Bioventus Germany GmbH (3) Germany Bioventus UK, Ltd (3) United Kingdom Misonix LLC (1) Delaware Misonix OpCo, LLC (4) Delaware Solsys Medical, LLC (4) Delaware Perseus |
|
| March 11, 2025 |
Form of Restricted Stock Unit Award Grant Notice and Restricted Stock Exhibit 10.15 BIOVENTUS, INC. 2021 EQUITY INCENTIVE PLAN RESTRICTED STOCK UNIT AWARD GRANT NOTICE AND RESTRICTED STOCK UNIT AGREEMENT Bioventus, Inc., a Delaware corporation (the “Company”), pursuant to its 2021 Equity Incentive Plan, as amended from time to time (the “Plan”), hereby grants to the holder listed below (“Participant”) the number of Restricted Stock Units set forth below (the “RSUs”) |
|
| March 11, 2025 |
BV1891 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37844 BIOVENT |
|
| March 11, 2025 |
Exhibit 4.2 DESCRIPTION OF CAPITAL STOCK The following description of the capital stock of Bioventus Inc. (the “Company,” “Bioventus,” “we,” and “our) and certain provisions of our Amended and Restated Certificate of Incorporation, as amended (the “Charter”) and our Second Amended and Restated Bylaws, are summaries and are qualified by reference to the Charter and the Second Amended and Restated B |
|
| March 11, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 11, 2025 Bioventus Inc. (Exact name of registrant as specified in charter) Delaware 001-37844 81-0980861 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| January 3, 2025 |
Bioventus Completes Divestiture of its Advanced Rehabilitation Business to Accelmed Partners Exhibit 99.1 Bioventus Completes Divestiture of its Advanced Rehabilitation Business to Accelmed Partners January 2, 2025 DURHAM, N.C., Jan. 02, 2025 (GLOBE NEWSWIRE) - Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, announced today that it has successfully completed the divestiture of its Advanced Rehabilitation business to Accelmed |
|
| January 3, 2025 |
Financial Statements and Exhibits, Completion of Acquisition or Disposition of Assets, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 31, 2024 Bioventus Inc. (Exact name of registrant as specified in charter) Delaware 001-37844 81-0980861 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| November 8, 2024 |
BVS / Bioventus Inc. / Spindletop Healthcare Capital, L.P. - SC 13G/A Passive Investment SC 13G/A Securities and Exchange Commission Washington, D.C. 20549 Schedule 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to § 240.13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to § 240.13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1)* Bioventus Inc. (Name of Issuer) Class A Common Stock (Title of Class of Securities) 09075A108 (CUSIP Num |
|
| November 5, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 5, 2024 Bioventus Inc. (Exact name of registrant as specified in charter) Delaware 001-37844 81-0980861 (State or other jurisdiction of incorporation) (Commission File Number |
|
| November 5, 2024 |
‘ m UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 28, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37844 B |
|
| November 5, 2024 |
Bioventus Reports Third Quarter Financial Results Exhibit 99.1 Bioventus Reports Third Quarter Financial Results •Q3 Revenue Advanced by 15.0%, Fourth Straight Quarter of Double Digit Organic* Growth •Q3 Gross Margin Expanded 200 bps •Q3 Cash from Operations of $10.3 million, an Increase of $18.6 million Compared to Previous Year DURHAM, NC – November 5, 2024 – Bioventus Inc. (Nasdaq: BVS) ("Bioventus" or the "Company"), a global leader in innova |
|
| November 4, 2024 |
Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-282836 PROSPECTUS BIOVENTUS INC. $200,000,000 Class A Common Stock Preferred Stock Debt Securities Warrants Units 35,038,052 Shares Class A Common Stock Offered by the Selling Securityholders We may offer and sell up to $200,000,000 in the aggregate of the securities identified above, and the selling securityholders may offer |
|
| November 1, 2024 |
Bioventus Inc. 4721 Emperor Boulevard, Suite 100 Durham, NC 27703 CORRESP Bioventus Inc. 4721 Emperor Boulevard, Suite 100 Durham, NC 27703 November 1, 2024 Via EDGAR Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Re: Bioventus Inc. Registration Statement on Form S-3 Filed October 25, 2024 File No. 333-282836 To whom it may concern: Pursuant to Rule 461(a) under the Securities |
|
| October 25, 2024 |
Exhibit 4.3 BIOVENTUS INC. INDENTURE Dated as of , 20 [] Trustee TABLE OF CONTENTS Page ARTICLE I. DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.1. Definitions 1 Section 1.2. Other Definitions 4 Section 1.3. Incorporation by Reference of Trust Indenture Act 5 Section 1.4. Rules of Construction 5 ARTICLE II. THE SECURITIES 5 Section 2.1. Issuable in Series 5 Section 2.2. Establishment of T |
|
| October 25, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Bioventus Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Fee |
|
| October 25, 2024 |
As filed with the Securities and Exchange Commission on October 25, 2024 Table of Contents As filed with the Securities and Exchange Commission on October 25, 2024 Registration No. |
|
| October 4, 2024 |
Bioventus LLC, Bioness Inc., Bioventus Cooperatief, U.A. and Rehab Acquisition Corporation, III EXECUTION VERSION PURCHASE AND SALE AGREEMENT by and among BIONESS INC., BIOVENTUS COOPERATIEF, U.A. and BIOVENTUS LLC collectively, as the Sellers and REHAB ACQUISITION CORPORATION, III as the Buyer Dated as of September 30, 2024 TABLE OF CONTENTS Page ARTICLE I DEFINITIONS 2 1.1 Definitions 2 1.2 Interpretative Provisions 23 ARTICLE II PURCHASE AND SALE 25 2.1 Purchase and Sale of the Transferre |
|
| October 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 30, 2024 Bioventus Inc. (Exact name of registrant as specified in charter) Delaware 001-37844 81-0980861 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| October 4, 2024 |
Bioventus Announces Divestiture of its Advanced Rehabilitation Business to Accelmed Partners Exhibit 99.1 Bioventus Announces Divestiture of its Advanced Rehabilitation Business to Accelmed Partners October 1, 2024 DURHAM, N.C., Oct. 01, 2024 (GLOBE NEWSWIRE) - Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, announced today that it has signed a definitive agreement to sell its Advanced Rehabilitation business of its subsidiar |
|
| August 6, 2024 |
Bioventus Reports Second Quarter Financial Results Exhibit 99.1 Bioventus Reports Second Quarter Financial Results •Q2 Revenue Advanced by 10.3%, Organic Growth* by 13.9% •Q2 Gross Margin Expanded 350 bps and Adjusted Gross Margin* 180 bps •Cash from Operations of $15.2 million Increased 40.5% •Raising Full-Year 2024 Financial Guidance Reflecting Enhanced Revenue Growth and Strong Execution of Strategic Priorities DURHAM, NC – August 6, 2024 – Bio |
|
| August 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2024 Bioventus Inc. (Exact name of registrant as specified in charter) Delaware 001-37844 81-0980861 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| August 6, 2024 |
‘ m UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 29, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37844 BIOVEN |
|
| July 19, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 19, 2024 Bioventus Inc. (Exact name of registrant as specified in charter) Delaware 001-37844 81-0980861 (State or other jurisdiction of incorporation) (Commission File Number) ( |
|
| July 15, 2024 |
BVS / Bioventus Inc. / AMP-CF Holdings, LLC - SC 13G/A Passive Investment SC 13G/A 1 d864688dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 3)* Bioventus Inc. (Name of Issuer) CLASS A COMMON STOCK, $0.001 PAR VALUE PER SHARE (Title of Class of Securities) 09075A108 (CUSIP Number) July 3, 2024 (Date of Event Which Requires Filing of this Statement) Check the |
|
| July 15, 2024 |
EX-99.1 2 d864688dex991.htm EX-99.1 CUSIP No. 09075A108 SCHEDULE 13G Page 15 of 16 Pages EXHIBIT 99.1 JOINT FILING AGREEMENT Each of the undersigned, pursuant to Rule 13d-1(k)(1) under the Act, hereby agrees and acknowledges that only one statement containing the information required by Schedule 13G need be filed with respect to the ownership by each of the undersigned of the Common Stock and the |
|
| June 21, 2024 |
Exhibit 10.1 AMENDMENT NO. 1 TO STOCKHOLDERS AGREEMENT This Amendment No. 1 to Stockholders Agreement (this “Amendment”) is entered into as of June 19, 2024 by and among (i) Bioventus Inc., a Delaware corporation (the “Company”), (ii) Bioventus LLC, a Delaware limited liability company (“Bioventus LLC”), (iii) the entities listed on Schedule 1 that are in existence on the date hereof (together wit |
|
| June 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 19, 2024 Bioventus Inc. (Exact name of registrant as specified in charter) Delaware 001-37844 81-0980861 (State or other jurisdiction of incorporation) (Commission File Number) ( |
|
| June 17, 2024 |
Certificate of Amendment to Amended and Restated Certificate of Incorporation of Bioventus Inc. Exhibit 3.1 CERTIFICATE OF AMENDMENT OF AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF BIOVENTUS INC. (pursuant to Section 242 of the General Corporation Law of the State of Delaware) Bioventus Inc. (the “Corporation”), a corporation organized and existing under the General Corporation Law of the State of Delaware, does hereby certify as follows: 1. The Board of Directors of the Corporation |
|
| June 17, 2024 |
Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 11, 2024 Bioventus Inc. (Exact name of registrant as specified in charter) Delaware 001-37844 81-0980861 (State or other jurisdiction of incorporation) (Commission File Number) ( |
|
| June 17, 2024 |
Second Amended and Restated Bylaws of Bioventus Inc. Exhibit 3.2 Second Amended and Restated Bylaws of BIOVENTUS INC. (a Delaware corporation) TABLE OF CONTENTS Page Article I - Corporate Offices 1 1.1 Registered Office 1 1.2 Other Offices 1 Article II - Meetings of Stockholders 1 2.1 Place of Meetings 1 2.2 Annual Meeting 1 2.3 Special Meeting 1 2.4 Notice of Business to be Brought before a Meeting 1 2.5 Notice of Nominations for Election to the Bo |
|
| June 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| May 7, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2024 Bioventus Inc. (Exact name of registrant as specified in charter) Delaware 001-37844 81-0980861 (State or other jurisdiction of incorporation) (Commission File Number) (IR |
|
| May 7, 2024 |
Bioventus Reports First Quarter Financial Results Exhibit 99.1 Bioventus Reports First Quarter Financial Results •Raises Full-Year 2024 Financial Guidance Reflecting Enhanced Revenue Growth and Strong Execution of Strategic Priorities •Accelerated First Quarter Revenue Growth by 8.7%, Organic Growth* by 15.3% •Gross Margin Expanded 620 bps and Adjusted Gross Margin* 190 bps DURHAM, NC – May 7, 2024 – Bioventus Inc. (Nasdaq: BVS) ("Bioventus" or t |
|
| May 7, 2024 |
‘ m` UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37844 BIOV |
|
| April 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| April 26, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| April 10, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| March 20, 2024 |
As filed with the Securities and Exchange Commission on March 20, 2024 As filed with the Securities and Exchange Commission on March 20, 2024 Registration No. |
|
| March 20, 2024 |
Exhibit 107.1 Calculation of Filing Fee Tables Form S-8 (Form Type) Bioventus Inc. (Exact Name of Registrant as Specified in its Charter) Table 1—Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount to be Registered (1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Class A common stock, $0. |
|
| March 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37844 BIOVENTUS INC. |
|
| March 12, 2024 |
Exhibit 21.1 Legal Name Jurisdiction of Incorporation Bioventus Inc. Delaware Bioventus LLC Delaware Bioventus Holdings LLC (1) North Carolina Bioventus Coöperatief U.A.(2) The Netherlands Bioventus Canada, Ulc (3) British Columbia Bioventus Germany GmbH (3) Germany Bioventus UK, Ltd (3) United Kingdom Misonix LLC (1) Delaware Misonix OpCo, LLC (4) Delaware Solsys Medical, LLC (4) Delaware Perseus |
|
| March 12, 2024 |
List of patents and pending patent applications directed to Bioventus Inc.’s material products Exhibit 99.1 List of patents issued and pending patent applications Country Application Number Filing Date Patent Number Application Status Expected Expiration Date Description Product AU 2009324417 40160 2009324417 Issued 47453 Directed to methods of making osteoinductive implants OsteoAMP AU 2014259553 41957 2014259553 Issued 47453 Directed to methods of making osteoinductive implants OsteoAMP A |
|
| March 12, 2024 |
Bioventus Announces Fourth Quarter and Full Year 2023 Financial Results Exhibit 99.1 Bioventus Announces Fourth Quarter and Full Year 2023 Financial Results •Accelerated fourth quarter sales growth to 7.6%, organic growth* of 14.3% •Appointed Rob Claypoole as President and Chief Executive Officer, bringing more than 20 years of leadership experience in the global medical device industry •Provides full-year 2024 financial guidance reflecting enhanced revenue growth and |
|
| March 12, 2024 |
Bioventus Inc. Compensation Recovery Policy, dated September 7, 2023. Exhibit 97.1 BIOVENTUS INC. COMPENSATION RECOVERY POLICY (As adopted by the Board of Directors on September 7, 2023) 1.Introduction The Board of Directors (the “Board”) of Bioventus Inc. (the “Company”) believes that it is in the best interests of the Company and its stockholders to create and maintain a culture that emphasizes integrity and accountability and that reinforces the Company’s pay-for |
|
| March 12, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 12, 2024 Bioventus Inc. (Exact name of registrant as specified in charter) Delaware 001-37844 81-0980861 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| February 14, 2024 |
BVS / Bioventus Inc. / Nantahala Capital Management, LLC - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* BIOVENTUS INC. (Name of Issuer) Class A Common Stock, $0.001 par value per share (Title of Class of Securities) 09075A108 (CUSIP Number) December 31, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the |
|
| February 6, 2024 |
EX-99.1 2 d938967dex991.htm EX-99.1 CUSIP No. 09075A108 SCHEDULE 13G Page 15 of 16 Pages EXHIBIT 99.1 JOINT FILING AGREEMENT Each of the undersigned, pursuant to Rule 13d-1(k)(1) under the Act, hereby agrees and acknowledges that only one statement containing the information required by Schedule 13G need be filed with respect to the ownership by each of the undersigned of the Common Stock and the |
|
| February 6, 2024 |
BVS / Bioventus Inc. / AMP-CF Holdings, LLC - SC 13G/A Passive Investment SC 13G/A 1 d938967dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 2)* Bioventus Inc. (Name of Issuer) CLASS A COMMON STOCK, $0.001 PAR VALUE PER SHARE (Title of Class of Securities) 09075A108 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Chec |
|
| January 22, 2024 |
EX-99.1 2 d676404dex991.htm EX-99.1 Exhibit 1 JOINT FILING AGREEMENT Each of the undersigned agrees that (i) the statement on Schedule 13G relating to the Class A Common Stock of Bioventus, Inc., has been adopted and filed on behalf of each of them, (ii) all future amendments to such statement on Schedule 13G/A will, unless written notice to the contrary is delivered as described below, be jointly |
|
| January 22, 2024 |
BVS / Bioventus Inc. / EW HEALTHCARE PARTNERS ACQUISITION FUND, L.P. - SC 13G/A Passive Investment SC 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* BIOVENTUS INC. (Name of Issuer) Class A Common Stock, par value $0.001 per share (Title of Class of Securities) 09075A108 (CUSIP Number) Martin P. Sutter EW Healthcare Partners Acquisition Fund, L.P. 21 Waterway Avenue, Suite 225 The Woodlands, Texas 77380 (2 |
|
| January 19, 2024 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 18, 2024 Bioventus Inc. (Exact name of registrant as specified in charter) Delaware 001-37844 81-0980861 (State or other jurisdiction of incorporation) (Commission File Number |
|
| January 19, 2024 |
Exhibit 10.1 EXECUTION VERSION AMENDMENT NO. 5 TO CREDIT AND GUARANTY AGREEMENT This AMENDMENT NO. 5 TO CREDIT AND GUARANTY AGREEMENT, dated as of January 18, 2024 (this “Amendment”), made by and among BIOVENTUS LLC, a Delaware limited liability company (the “Borrower”), the Guarantor Subsidiaries party hereto, the Lenders party hereto (the “Consenting Lenders”) and WELLS FARGO BANK, NATIONAL ASSO |
|
| January 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 9, 2024 Bioventus Inc. (Exact name of registrant as specified in charter) Delaware 001-37844 81-0980861 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| January 9, 2024 |
As filed with the Securities and Exchange Commission on January 9, 2024 As filed with the Securities and Exchange Commission on January 9, 2024 Registration No. |
|
| January 9, 2024 |
Exhibit 107.1 Calculation of Filing Fee Tables Form S-8 (Form Type) Bioventus Inc. (Exact Name of Registrant as Specified in its Charter) Table 1—Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount to be Registered (1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Class A common stock, $0. |
|
| December 21, 2023 |
Form of Bioventus Inc. Inducement Award - Restricted Stock Unit Agreement. Exhibit 10.2 BIOVENTUS INC. RESTRICTED STOCK UNIT GRANT NOTICE (Inducement Award) Bioventus Inc., a Delaware corporation (the “Company”), hereby grants to the individual listed below (“Holder”) the number of Restricted Stock Units set forth below (the “RSUs”). The RSUs are subject to the terms and conditions set forth in this Restricted Stock Unit Grant Notice (the “Grant Notice”) and the Restrict |
|
| December 21, 2023 |
Bioventus Names Robert Claypoole as President and Chief Executive Officer Exhibit 99.1 Bioventus Names Robert Claypoole as President and Chief Executive Officer Seasoned Leader Brings More than Two Decades of Medical Device Experience and Proven Track Record of Driving Revenue and Operating Margin Growth DURHAM, N.C., Dec. 19, 2023 (GLOBE NEWSWIRE) – Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today ann |
|
| December 21, 2023 |
Employment Agreement, between Robert E. Claypoole and Bioventus Inc. Exhibit 10.1 Bioventus 4721 Emperor Blvd., Suite 100 Durham, NC 27703 USA 1-919-474-6700 1-800-396-4325 www.BioventusGlobal.com December 19, 2023 Robert E. Claypoole 204 Affirmed Court Milton, GA 30004 Re: Employment Agreement Dear Rob: I am pleased to offer you employment in the position of President and Chief Executive Officer of Bioventus Inc. (the “Corporation”) on the terms set forth in this |
|
| December 21, 2023 |
Form of Bioventus Inc. Inducement Award - Option Agreement. Exhibit 10.3 BIOVENTUS INC. NOTICE OF STOCK OPTION GRANT (Inducement Award) Name of Holder: Robert E. Claypoole Date of Grant: January 11, 2024 Exercise Price per Share: The exercise price for the Stock Option Inducement Award will be the closing price of the Corporation’s Common Stock on the Date of Grant. Total Number of Shares Subject to Option Granted: 850,000 Type of Option Nonstatutory Stock |
|
| December 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 19, 2023 Bioventus Inc. (Exact name of registrant as specified in charter) Delaware 001-37844 81-0980861 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| November 7, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2023 Bioventus Inc. (Exact name of registrant as specified in charter) Delaware 001-37844 81-0980861 (State or other jurisdiction of incorporation) (Commission File Number |
|
| November 7, 2023 |
Exhibit 99.1 Bioventus Reports Third Quarter Financial Results; Raises Full Year 2023 Financial Guidance DURHAM, NC – November 7, 2023 – Bioventus Inc. (Nasdaq: BVS) ("Bioventus" or "the Company"), a global leader in innovations for active healing, today reported financial results for the three and nine months ended September 30, 2023. Q3 Financial Summary: •Net Sales of $120.8 million, down $7.9 |
|
| November 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37844 BIOVE |
|
| August 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended July 1, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37844 BIOVENTUS I |
|
| August 8, 2023 |
Exhibit 99.1 Bioventus Reports Second Quarter Financial Results; Introduces Full Year 2023 Financial Guidance DURHAM, NC – August 8, 2023 – Bioventus Inc. (Nasdaq: BVS) ("Bioventus" or "the Company"), a global leader in innovations for active healing, today reported financial results for the three and six months ended July 1, 2023. Q2 Financial Summary: •Net Sales of $137.1 million, down $3.3 mill |
|
| August 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2023 Bioventus Inc. (Exact name of registrant as specified in charter) Delaware 001-37844 81-0980861 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| June 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3) Bioventus, Inc. (Name of Issuer) Class A Common Stock, $0.001 par value per share (Title of Class of Securities) 09075A108 (CUSIP Number) John A. Bartholdson Juniper Investment Company, LLC 555 Madison Avenue, 24th Floor New York, New York 10022 (212) 339 |
|
| June 16, 2023 |
As filed with the Securities and Exchange Commission on June 16, 2023 As filed with the Securities and Exchange Commission on June 16, 2023 Registration No. |
|
| June 16, 2023 |
Exhibit 107.1 Calculation of Filing Fee Tables Form S-8 (Form Type) Bioventus Inc. (Exact Name of Registrant as Specified in its Charter) Table 1—Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount to be Registered (1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Class A common stock, $0. |
|
| June 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 7, 2023 Bioventus Inc. (Exact name of registrant as specified in charter) Delaware 001-37844 81-0980861 (State or other jurisdiction of incorporation) (Commission File Number) (I |
|
| June 9, 2023 |
Form of Restricted Stock Unit Award Grant Notice and Restricted Stock Unit Agreement. Exhibit 10.2 BIOVENTUS INC. 2023 RETENTION EQUITY AWARD PLAN RESTRICTED STOCK UNIT GRANT NOTICE Bioventus Inc., a Delaware corporation (the “Company”), pursuant to its 2023 Retention Equity Award Plan, as amended from time to time (the “Plan”), hereby grants to the individual listed below (“Participant”) the number of Restricted Stock Units set forth below (the “Units”). The Units are subject to t |
|
| June 9, 2023 |
Bioventus Inc. 2023 Retention Equity Award Plan Exhibit 10.1 BIOVENTUS INC. 2023 RETENTION EQUITY AWARD PLAN 2023 Retention Equity Award Plan Approved by the Board on April 17, 2023 and by the Stockholders on June 7, 2023 1.Purposes of the Plan. The purposes of this Plan are to retain critical personnel serving as Employees; to provide additional incentives to Employees to contribute to the successful performance of the Company and any Related |
|
| May 26, 2023 |
UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION Exhibit 99.2 UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION The following unaudited pro forma condensed combined financial information of Bioventus Inc. (together with its subsidiaries, the “Company” or “Bioventus”) has been prepared to illustrate the estimated effects of the Wound Divestiture, the CartiHeal Deconsolidation, and the Financing Transactions described in Note 1. Descrip |
|
| May 26, 2023 |
Bioventus Completes Divestiture of its Wound Business Exhibit 99.1 Bioventus Completes Divestiture of its Wound Business May 23, 2023 DURHAM, N.C., May 23, 2023 (GLOBE NEWSWIRE) - Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, announced today that it has successfully completed the divestiture of its Wound business, including the skin substitutes TheraSkin and TheraGenesis, to LifeNet He |
|
| May 26, 2023 |
Financial Statements and Exhibits, Completion of Acquisition or Disposition of Assets, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 22, 2023 Bioventus Inc. (Exact name of registrant as specified in charter) Delaware 001-37844 81-0980861 (State or other jurisdiction of incorporation) (Commission File Number) (I |
|
| May 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2) Bioventus, Inc. (Name of Issuer) Class A Common Stock, $0.001 par value per share (Title of Class of Securities) 09075A108 (CUSIP Number) John A. Bartholdson Juniper Investment Company, LLC 555 Madison Avenue, 24th Floor New York, New York 10022 (212) 339 |
|
| May 16, 2023 |
EX-2.1 Exhibit 2.1 EXECUTION VERSION ASSET PURCHASE AGREEMENT by and among MISONIX, LLC, SOLSYS MEDICAL, LLC and BIOVENTUS LLC collectively, as the Sellers and LIFENET HEALTH as the Buyer Dated as of May 10, 2023 TABLE OF CONTENTS Page ARTICLE I DEFINITIONS 1 1.1 Definitions 1 1.2 Interpretative Provisions 13 ARTICLE II PURCHASE AND SALE 14 2.1 Purchase and Sale of Assets; Assumption of Liabilitie |
|
| May 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended April 1, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37844 BIOVENTUS |
|
| May 16, 2023 |
Bioventus Announces Divestiture of its Wound Business EX-99.1 Exhibit 99.1 Bioventus Announces Divestiture of its Wound Business DURHAM, N.C., May 10, 2023 (GLOBE NEWSWIRE) — Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, announced today that it has signed a definitive agreement to sell its Wound business, including the skin substitutes TheraSkin and TheraGenesis, to LifeNet Health. The |
|
| May 16, 2023 |
Consulting Agreement between Alessandra Pavesio and Bioventus LLC, dated as of January 1, 2023. Exhibit 10.1 || BIOVENTUS LLC CONSULTING AGREEMENT This CONSULTING AGREEMENT (this “Agreement”) is made between Bioventus LLC (the “Company”) and Alessandra Pavesio (“Consultant”) effective as of January 1, 2023 (the “Effective Date”). This Agreement sets forth the terms and conditions by which the Company will engage Consultant to perform certain services for the Company as further described belo |
|
| May 16, 2023 |
Exhibit 99.1 Bioventus Reports First Quarter Financial Results DURHAM, NC – May 16, 2023 – Bioventus Inc. (Nasdaq: BVS) ("Bioventus" or "the Company"), a global leader in innovations for active healing, today reported financial results for the three months ended April 1, 2023. Q1 Financial Summary: •Net Sales of $119.1 million, up $1.8 million, or 1.5%, year-over-year as reported (1.9% constant cu |
|
| May 16, 2023 |
Exhibit 10.3 Execution Copy February 27, 2023 Settlement Agreement Reference is hereby made to (i) that certain Option and Equity Purchase Agreement, dated July 15, 2020, by and among CartiHeal (2009) Ltd. (the “Company”), Bioventus LLC (the “Buyer”), Elron Ventures Ltd. (the “Securityholder Representative”) and certain other parties detailed therein, as amended by an Amendment to the Option and E |
|
| May 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2023 Bioventus Inc. (Exact name of registrant as specified in charter) Delaware 001-37844 81-0980861 (State or other jurisdiction of incorporation) (Commission File Number) (I |
|
| May 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 16, 2023 Bioventus Inc. (Exact name of registrant as specified in charter) Delaware 001-37844 81-0980861 (State or other jurisdiction of incorporation) (Commission File Number) (I |
|
| May 11, 2023 |
NT 10-Q 1 nt-10qq12023.htm NT 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR SEC File Number: 001-37844 CUSIP Number: 09075A108 For Period Ended: April 1, 2023 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Tra |
|
| May 11, 2023 |
Exhibit 99.1 Bioventus Reschedules Earnings Call to May 16, 2023 Files for Extension to File Form 10-Q for the Period Ended April 1, 2023 DURHAM, NC – May 11, 2023 – Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, announced today the Company plans to file Form 12b-25, Notification of Late Filing, for its Quarterly Report on Form 10-Q |
|
| May 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2023 Bioventus Inc. (Exact name of registrant as specified in charter) Delaware 001-37844 81-0980861 (State or other jurisdiction of incorporation) (Commission File Number) (I |
|
| April 27, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| April 27, 2023 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| April 18, 2023 |
As filed with the Securities and Exchange Commission on April 18, 2023 As filed with the Securities and Exchange Commission on April 18, 2023 Registration No. |
|
| April 18, 2023 |
Exhibit 107.1 Calculation of Filing Fee Tables Form S-8 (Form Type) Bioventus Inc. (Exact Name of Registrant as Specified in its Charter) Table 1—Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount to be Registered (1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Class A common stock, $0. |
|
| April 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 3, 2023 Bioventus Inc. (Exact name of registrant as specified in charter) Delaware 001-37844 81-0980861 (State or other jurisdiction of incorporation) (Commi |
|
| April 11, 2023 |
Employment Agreement between Anthony P. Bihl III and Bioventus Inc., dated as of April 5, 2023. EX-10.1 Exhibit 10.1 Bioventus 1-919-474-6700 4721 Emperor Blvd., Suite 100 1-800-396-4325 Durham, NC 27703 www.BioventusGlobal.com USA April 5, 2023 Re: Employment Agreement Dear Tony, I am pleased to offer you employment at Bioventus LLC (“Bioventus” or the “Company”) on the terms set forth in this offer letter agreement (the “Agreement”). This Agreement will be effective on April 5, 2023 or a m |
|
| April 5, 2023 |
Separation Agreement and Release between Kenneth Reali and Bioventus Inc., dated April 4, 2023 EX-10.1 Exhibit 10.1 Separation Agreement and Release This Separation Agreement and Release (“Agreement”) is made by and between Kenneth Reali (“Executive”) and Bioventus Inc. (the “Corporation”) and Bioventus LLC (the “Partnership” and, together with the Corporation and any affiliates of the Corporation or the Partnership that may have employed Executive from time to time, the “Company”) (collect |
|
| April 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 3, 2023 Bioventus Inc. (Exact name of registrant as specified in charter) Delaware 001-37844 81-0980861 (State or other jurisdiction of incorporation) (Commission File Number) ( |
|
| March 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37844 BIOVENTUS INC. |
|
| March 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2023 Bioventus Inc. (Exact name of registrant as specified in charter) Delaware 001-37844 81-0980861 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| March 31, 2023 |
List of patents and pending patent applications directed to Bioventus Inc.’s material products Exhibit 99.1 List of patents issued and pending patent applications Country Application Number Filing Date Patent Number Application Status Expected Expiration Date Description Product AU 2009324417 December 13, 2009 2009324417 Issued Dec-29 Directed to methods of making osteoinductive implants OsteoAMP AU 2014259553 November 14, 2014 2014259553 Issued Dec-29 Directed to methods of making osteoind |
|
| March 31, 2023 |
Bioventus Reports Fourth Quarter and Full-Year 2022 Financial Results Exhibit 99.1 Bioventus Reports Fourth Quarter and Full-Year 2022 Financial Results DURHAM, NC – March 31, 2023 – Bioventus Inc. (Nasdaq: BVS) ("Bioventus" or "the Company"), a global leader in innovations for active healing, today reported financial results for the year ended December 31, 2022. Q4 Financial Summary & Recent Highlights: •Net Sales of $125.8 million, down $4.6 million, or (3.5%), ye |
|
| March 31, 2023 |
Exhibit 10.8(d) AMENDMENT NO. 4 TO CREDIT AND GUARANTY AGREEMENT This AMENDMENT NO. 4 TO CREDIT AND GUARANTY AGREEMENT, dated as of March 31, 2023 (this “Amendment”), made by and among BIOVENTUS LLC, a Delaware limited liability company (“Borrower”), the Guarantor Subsidiaries party hereto, the Lenders party hereto (the “Consenting Lenders”) and WELLS FARGO BANK, NATIONAL ASSOCIATION, as Administr |
|
| March 31, 2023 |
Exhibit 21.1 Legal Name Jurisdiction of Incorporation Bioventus Inc. Delaware Bioventus LLC Delaware Bioventus Holdings LLC (1) North Carolina Bioventus Coöperatief U.A.(2) The Netherlands Bioventus Canada, Ulc (3) British Columbia Bioventus Germany GmbH (3) Germany Bioventus UK, Ltd (3) United Kingdom CartiHeal (2009) Ltd. (4) Israel CartiHeal Inc. (5) New Jersey Misonix LLC (1) Delaware Misonix |
|
| March 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): ☒ Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR SEC File Number: 001-37844 CUSIP Number: 09075A108 For Period Ended: December 31, 2022 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ T |
|
| March 3, 2023 |
Financial Statements and Exhibits, Completion of Acquisition or Disposition of Assets UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 27, 2023 Bioventus Inc. (Exact name of registrant as specified in charter) Delaware 001-37844 81-0980861 (State or other jurisdiction of incorporation) (Com |
|
| March 3, 2023 |
UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION Exhibit 99.1 UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION On July 12, 2022 (the “Purchase Date”), Bioventus LLC (“LLC”), a subsidiary of Bioventus Inc. (together with its subsidiaries, the “Company” or "Bioventus") completed the acquisition of 100% of the remaining shares of CartiHeal (2009) Ltd. (“CartiHeal”), pursuant to the Option and Equity Purchase Agreement, dated July 15, 20 |
|
| February 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 27, 2023 Bioventus Inc. (Exact name of registrant as specified in charter) Delaware 001-37844 81-0980861 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| February 14, 2023 |
BVS / Bioventus Inc. Class A / Nantahala Capital Management, LLC - SC 13G Passive Investment SC 13G 1 tm236168d9sc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* BIOVENTUS INC. (Name of Issuer) Class A Common Stock, $0.001 par value per share (Title of Class of Securities) (CUSIP Number) December 31, 2022 (Date of Event which Requires Filing of this Statement) Check the appropri |
|
| February 7, 2023 |
BVS / Bioventus Inc. Class A / AMP-CF Holdings, LLC - SC 13G/A Passive Investment SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1)* Bioventus Inc. (Name of Issuer) CLASS A COMMON STOCK, $0.001 PAR VALUE PER SHARE (Title of Class of Securities) 09075A108 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to desig |
|
| February 7, 2023 |
EX-99.1 CUSIP No. 09075A108 SCHEDULE 13G Page 1 5 of 16 Pages EXHIBIT 99.1 JOINT FILING AGREEMENT Each of the undersigned, pursuant to Rule 13d-1(k)(1) under the Act, hereby agrees and acknowledges that only one statement containing the information required by Schedule 13G need be filed with respect to the ownership by each of the undersigned of the Common Stock and the information required by thi |
|
| January 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 8, 2023 Bioventus Inc. (Exact name of registrant as specified in charter) Delaware 001-37844 81-0980861 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| December 7, 2022 |
Costs Associated with Exit or Disposal Activities UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 7, 2022 Bioventus Inc. (Exact name of registrant as specified in charter) Delaware 001-37844 81-0980861 (State or other jurisdiction of incorporation) (Commission File Number |
|
| November 21, 2022 |
Bioventus Issues Revised Third Quarter Results; Updates Full-Year 2022 Financial Guidance Exhibit 99.1 Bioventus Issues Revised Third Quarter Results; Updates Full-Year 2022 Financial Guidance DURHAM, NC – November 21, 2022 – Bioventus Inc. (Nasdaq: BVS) ("Bioventus" or "the Company"), a global leader in innovations for active healing, today amended its previously announced financial results for the three and nine months ended October 1, 2022. Due to the adverse effect on the previousl |
|
| November 21, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 8, 2022 Bioventus Inc. (Exact name of registrant as specified in charter) Delaware 001-37844 81-0980861 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| November 21, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended October 1, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: |
|
| November 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): ? Form 10-K ? Form 20-F ? Form 11-K ? Form 10-Q ? Form 10-D ? Form N-CEN ? Form N-CSR SEC File Number: 001-37844 CUSIP Number: 09075A108 For Period Ended: October 1, 2022 ? Transition Report on Form 10-K ? Transition Report on Form 20-F ? Transition Report on Form 11-K ? Tra |
|
| November 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 16, 2022 Bioventus Inc. (Exact name of registrant as specified in charter) Delaware 001-37844 81-0980861 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| November 16, 2022 |
Bioventus Files for Extension to File Form 10-Q for the Period Ended October 1, 2022 Bioventus Files for Extension to File Form 10-Q for the Period Ended October 1, 2022 DURHAM, NC – November 16, 2022 – Bioventus Inc. |
|
| November 15, 2022 |
BVS / Bioventus Inc. Class A / Juniper Investment Company, LLC - AMENDMENT NO. 1 Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1*) Bioventus, Inc. (Name of Issuer) Class A Common Stock, $0.001 par value per share (Title of Class of Securities) 09075A108 (CUSIP Number) John A. Bartholdson Juniper Investment Company, LLC 555 Madison Avenue, 24th Floor New York, New York 10022 (212) 33 |
|
| November 8, 2022 |
Bioventus Reports Third Quarter Results; Updates Full-Year 2022 Financial Guidance Exhibit 99.1 Bioventus Reports Third Quarter Results; Updates Full-Year 2022 Financial Guidance DURHAM, NC – November 8, 2022 – Bioventus Inc. (Nasdaq: BVS) ("Bioventus" or "the Company"), a global leader in innovations for active healing, today reported financial results for the three and nine months ended October 1, 2022. Q3 Financial Summary & Recent Highlights: •Net Sales of $137.1 million, up |
|
| November 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 8, 2022 Bioventus Inc. (Exact name of registrant as specified in charter) Delaware 001-37844 81-0980861 (State or other jurisdiction of incorporation) (Commission File Number |
|
| September 27, 2022 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 12, 2022 Bioventus Inc. (Exact name of registrant as specified in charter) Delaware 001-37844 81-0980861 (State or other jurisdiction of incorporation) (Commi |
|
| September 27, 2022 |
CARTIHEAL (2009) LTD. 2021 CONSOLIDATED FINANCIAL STATEMENTS TABLE OF CONTENTS Exhibit 99.1 CARTIHEAL (2009) LTD. 2021 CONSOLIDATED FINANCIAL STATEMENTS TABLE OF CONTENTS Page REPORT OF INDEPENDENT AUDITORS 1 CONSOLIDATED FINANCIAL STATEMENTS - U.S. DOLLARS IN THOUSANDS: Consolidated Statements of Financial Position 3 Consolidated Statements of Comprehensive Loss 4 Consolidated Statements of Changes in Equity 5 Consolidated Statements of Cash Flows 6 Notes to Consolidated Fi |
|
| September 27, 2022 |
UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION Exhibit 99.2 UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION On July 12, 2022, Bioventus, Inc. (together with its subsidiaries, ?Bioventus? or the ?Company?) completed the acquisition of 100% of the remaining shares of CartiHeal (2009) Ltd. (?CartiHeal?), a privately held company headquartered in Israel and the developer of the proprietary Agili-C implant for the treatment of joint su |
|
| September 1, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 31, 2022 Bioventus Inc. (Exact name of registrant as specified in charter) Delaware 001-37844 81-0980861 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| August 12, 2022 |
Bioventus Inc. 2021 Equity Incentive Plan. Exhibit 10.3 BIOVENTUS INC. 2021 EQUITY INCENTIVE PLAN ARTICLE 1. PURPOSE The purpose of the Bioventus Inc. 2021 Equity Incentive Plan (as it may be amended or restated from time to time, the ?Plan?) is to promote the success and enhance the value of Bioventus Inc. (the ?Company?) by linking the individual interests of the members of the Board, Employees, and Consultants to those of Company stockh |
|
| August 12, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended July 2, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001 |
|
| August 11, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2022 Bioventus Inc. (Exact name of registrant as specified in charter) Delaware 001-37844 81-0980861 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| August 11, 2022 |
Bioventus Reports Second Quarter Results; Updates Full-Year 2022 Financial Guidance Exhibit 99.1 Bioventus Reports Second Quarter Results; Updates Full-Year 2022 Financial Guidance DURHAM, NC ? August 11, 2022 ? Bioventus Inc. (Nasdaq: BVS) ("Bioventus" or "the Company"), a global leader in innovations for active healing, today reported financial results for the three and six months ended July 2, 2022. Q2 Financial Summary & Recent Highlights: ?Net Sales of $140.3 million, up $30 |
|
| July 21, 2022 |
BVS / Bioventus Inc. Class A / Juniper Investment Company, LLC Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 Bioventus, Inc. (Name of Issuer) Class A Common Stock, $0.001 par value per share (Title of Class of Securities) 09075A108 (CUSIP Number) John A. Bartholdson Juniper Investment Company, LLC 555 Madison Avenue, 24th Floor New York, New York 10022 (212) 339-8500 (Name, Addre |
|
| July 12, 2022 |
Exhibit 10.1 Execution Version AMENDMENT NO. 3 TO CREDIT AND GUARANTY AGREEMENT THIS AMENDMENT NO. 3 TO CREDIT AND GUARANTY AGREEMENT, dated as of July 11, 2022 (this ?Amendment?), made by and among BIOVENTUS LLC, a Delaware limited liability company (?Borrower?), the Guarantor Subsidiaries party hereto, the Lenders party hereto (the ?Consenting Lenders?) and WELLS FARGO BANK, NATIONAL ASSOCIATION |
|
| July 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 12, 2022 Bioventus Inc. (Exact name of registrant as specified in charter) Delaware 001-37844 81-0980861 (State or other jurisdiction of incorporation) (Commission File Number) ( |
|
| June 29, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 27, 2022 Bioventus Inc. (Exact name of registrant as specified in charter) Delaware 001-37844 81-0980861 (State or other jurisdiction of incorporation) (Commission File Number) ( |
|
| June 22, 2022 |
Exhibit 10.1 AMENDMENT TO OPTION AND EQUITY PURCHASE AGREEMENT THIS AMENDMENT (this ?Amendment?), entered into and effective as of June 17, 2022, is made by and among (a) Bioventus LLC, a Delaware limited liability company (?Buyer?), (b) CartiHeal (2009) Ltd., an Israeli private company registered under number 514279645 (the ?Company?) and (c) Elron Ventures Ltd. (formerly known as Elron Electroni |
|
| June 22, 2022 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 17, 2022 Bioventus Inc. (Exact name of registrant as specified in charter) Delaware 001-37844 81-0980861 (State or other jurisdiction of incorporation) (Commission File Number) ( |
|
| June 21, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 17, 2022 Bioventus Inc. (Exact name of registrant as specified in charter) Delaware 001-37844 81-0980861 (State or other jurisdiction of incorporation) (Commission File Number) ( |
|
| May 11, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended April 2, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 00 |
|
| May 10, 2022 |
Bioventus Reports First Quarter Results; Reaffirms Full-Year 2022 Financial Guidance Exhibit 99.1 Bioventus Reports First Quarter Results; Reaffirms Full-Year 2022 Financial Guidance DURHAM, NC ? May 10, 2022 ? Bioventus Inc. (Nasdaq: BVS) ("Bioventus" or "the Company"), a global leader in innovations for active healing, today reported financial results for three months ended April 2, 2022. Q1 Financial Summary & Recent Highlights: ?Net Sales of $117.3 million, up $35.5 million, o |
|
| May 10, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2022 Bioventus Inc. (Exact name of registrant as specified in charter) Delaware 001-37844 81-0980861 (State or other jurisdiction of incorporation) (Commission File Number) (I |
|
| April 29, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| April 29, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| April 26, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 26, 2022 Bioventus Inc. (Exact name of registrant as specified in charter) Delaware 001-37844 81-0980861 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| April 26, 2022 |
SUMMARY HISTORICAL AND PRO FORMA CONSOLIDATED FINANCIAL INFORMATION Exhibit 99.3 Our Company We are a global medical device company focused on developing and commercializing clinically differentiated, cost efficient and minimally invasive treatments that engage and enhance the body?s natural healing process. We manage our business through two reporting segments, U.S. and International, which accounted for 90% and 10%, respectively, of our total net sales during th |
|
| April 26, 2022 |
Misonix, Inc. and Subsidiaries Condensed Consolidated Balance Sheets Exhibit 99.4 PART I - FINANCIAL INFORMATION Page Item 1. Financial Statements Condensed Consolidated Balance Sheets (Unaudited) as of September 30, 2021 and the Consolidated Balance Sheets as of June 30, 2021 2 Condensed Consolidated Statements of Operations (Unaudited) for the three months ended September 30, 2021 and 2020 3 Condensed Consolidated Statement of Shareholders? Equity (Unaudited) for |
|
| April 26, 2022 |
NEWS Bioventus Announces $415 Million Offering of Senior Notes Exhibit 99.2 NEWS Bioventus Announces $415 Million Offering of Senior Notes DURHAM, NC ? April 26, 2022 ? Bioventus Inc. (Nasdaq: BVS) (?Bioventus? or the ?Company?), a global leader in innovations for active healing, announced today that, subject to market conditions, its subsidiary Bioventus LLC (the ?Issuer?) intends to offer for sale $415 million in aggregate principal amount of its senior not |
|
| April 26, 2022 |
Bioventus Announces Preliminary First Quarter Net Sales and Adjusted EBITDA Exhibit 99.1 NEWS Bioventus Announces Preliminary First Quarter Net Sales and Adjusted EBITDA DURHAM, NC ? April 26, 2022 ? Bioventus Inc. (Nasdaq: BVS) (?Bioventus? or the ?Company?), a global leader in innovations for active healing, announced today preliminary financial results for the first quarter ended April 2, 2022. Preliminary First Quarter Net Sales and Adjusted EBITDA Preliminary, unaudi |
|
| April 26, 2022 |
Exhibit 99.5 UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION (Dollar amounts presented in millions, except share data) On January 30, 2018, the Company purchased 337,397 shares of Series F Convertible Preferred Stock of CartiHeal (2009) Ltd. (CartiHeal), a privately held entity, for $2,500. On January 22, 2020, the Company made an additional $152 investment in CartiHeal, through a Sim |
|
| April 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 4, 2022 Bioventus Inc. (Exact name of registrant as specified in charter) Delaware 001-37844 81-0980861 (State or other jurisdiction of incorporation) (Commission File Number) ( |
|
| April 1, 2022 |
Exhibit 107.1 Calculation of Filing Fee Tables Form S-8 (Form Type) Bioventus Inc. (Exact Name of Registrant as Specified in its Charter) Table 1?Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount to be Registered (1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Class A common stock, $0. |
|
| April 1, 2022 |
Bioventus Inc. Notice of Stock Option Grant Inducement Award Exhibit 99.2 BIOVENTUS INC. NOTICE OF STOCK OPTION GRANT INDUCEMENT AWARD Name of Holder: Mark Singleton Address: [l] Date of Grant: [l] Exercise Price per Share: $[l] Total Number of Shares Subject to Option Granted: [l] Type of Option: Incentive Stock Option X Nonstatutory Stock Option Expiration Date: [l] Vesting Commencement Date: [l] Vesting Schedule: This Option shall be exercisable, in whol |
|
| April 1, 2022 |
As filed with the Securities and Exchange Commission on April 1, 2022 As filed with the Securities and Exchange Commission on April 1, 2022 Registration No. |
|
| April 1, 2022 |
Exhibit 99.1 BIOVENTUS INC. RESTRICTED STOCK UNIT AWARD Grant Notice and restricted stock unit agreement INDUCEMENT AWARD Bioventus Inc., a Delaware corporation (the ?Company?), hereby grants to the holder listed below (?Holder?) the number of Restricted Stock Units set forth below (the ?RSUs?). The RSUs are subject to the terms and conditions set forth in this Restricted Stock Unit Grant Notice ( |
|
| March 11, 2022 |
Exhibit 107.1 Calculation of Filing Fee Tables Form S-8 (Form Type) Bioventus Inc. (Exact Name of Registrant as Specified in its Charter) Table 1?Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount to be Registered (1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Class A common stock, $0. |
|
| March 11, 2022 |
Table of Contents h UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| March 11, 2022 |
List of patents and pending patent applications directed to Bioventus Inc.’s material products Exhibit 99.1 List of patents issued and pending patent applications Country Application Number Filing Date Patent Number Application Status Expected Expiration Date Description Product AU 2009324417 December 13, 2009 2009324417 Issued December 2029 Directed to methods of making osteoinductive implants OsteoAMP AU 2014259553 November 14, 2014 2014259553 Issued December 2029 Directed to methods of m |
|
| March 11, 2022 |
As filed with the Securities and Exchange Commission on March 11, 2022 As filed with the Securities and Exchange Commission on March 11, 2022 Registration No. |
|
| March 11, 2022 |
List of subsidiaries of Bioventus Inc. Exhibit 21.1 Legal Name Jurisdiction of Incorporation Bioventus Inc. Delaware Bioventus LLC Delaware Bioventus Holdings LLC (1) North Carolina Bioventus Co?peratief U.A.(2) The Netherlands Bioventus Canada, Ulc (3) British Columbia Bioventus Germany GmbH (3) Germany Bioventus UK, Ltd (3) United Kingdom CartiHeal (2009) Ltd. (4) Israel Misonix LLC (1) Delaware Misonix OpCo, LLC (5) Delaware Perseus |
|
| March 10, 2022 |
Exhibit 99.1 Bioventus Reports Fourth Quarter and Full Year 2021 Financial Results; Introduces Full Year 2022 Financial Guidance DURHAM, NC ? March 10, 2022 ? Bioventus Inc. (Nasdaq: BVS) ("Bioventus" or "the Company"), a global leader in innovations for active healing, today reported financial results for the fourth quarter and full-year ended December 31, 2021. Fourth Quarter Financial Summary & |
|
| March 10, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2022 Bioventus Inc. (Exact name of registrant as specified in charter) Delaware 001-37844 81-0980861 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| February 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2022 Bioventus Inc. (Exact name of registrant as specified in charter) Delaware 001-37844 81-0980861 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| February 28, 2022 |
Exhibit 10.1 Bioventus 1-919-474-6700 4721 Emperor Blvd., Suite 100 1-800-396-4325 Durham, NC 27703 www.BioventusGlobal.com USA February 14, 2022 Mark Singleton Re: Revised Employment Agreement Dear Mark, I am pleased to offer you employment at Bioventus LLC (?Bioventus? or the ?Company?) on the terms set forth in this offer letter agreement (the ?Agreement?). This Agreement will be effective on M |
|
| February 25, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 25, 2022 Bioventus Inc. (Exact name of registrant as specified in charter) Delaware 001-37844 81-0980861 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| February 11, 2022 |
BVS / Bioventus Inc. Class A / AMP-CF Holdings, LLC - SC 13G Passive Investment SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )* Bioventus Inc. (Name of Issuer) CLASS A COMMON STOCK, $0.001 PAR VALUE PER SHARE (Title of Class of Securities) 09075A108 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designat |
|
| February 11, 2022 |
SCHEDULE 13G CUSIP No. 09075A108 Page 15 of 16 Pages EXHIBIT 99.1 JOINT FILING AGREEMENT Each of the undersigned, pursuant to Rule 13d-1(k)(1) under the Act, hereby agrees and acknowledges that only one statement containing the information required by Schedule 13G need be filed with respect to the ownership by each of the undersigned of the Common Stock and the information required by this Schedul |
|
| February 10, 2022 |
Exhibit 99 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that they are jointly filing this statement on Schedule 13G. |
|
| February 10, 2022 |
BVS / Bioventus Inc. Class A / Spindletop Healthcare Capital, L.P. - SC 13G Passive Investment SC 13G 1 d282101dsc13g.htm SC 13G Securities and Exchange Commission Washington, D.C. 20549 Schedule 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to § 240.13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to § 240.13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )* Bioventus Inc. (Name of Issuer) Class A Common Stock (Title of Class of Securiti |
|
| February 7, 2022 |
BVS / Bioventus Inc. Class A / SMITH & NEPHEW PLC - FORM SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.)* BIOVENTUS INC. (Name of Issuer) Class A common stock, par value $0.001 per share (Title of Class of Securities) 09075A108 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the ru |
|
| February 7, 2022 |
EX-99.1 2 dp166555ex9901.htm EXHIBIT I EXHIBIT I JOINT FILING AGREEMENT This will confirm the agreement by and among the undersigned that the Schedule 13G filed with the Securities and Exchange Commission on or about the date hereof with respect to the beneficial ownership by the undersigned of the Class A common stock, par value $0.001 per share, of Bioventus Inc., will be filed on behalf of each |
|
| January 31, 2022 |
SC 13G SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* BIOVENTUS INC. (Name of Issuer) Class A Common Stock, par value $0.001 per share (Title of Class of Securities) 09075A108 (CUSIP Number) Martin P. Sutter EW Healthcare Partners Acquisition Fund, L.P. 21 Waterway Avenue, Suite 225 The Woodlands, Texas 77380 (281) |
|
| January 31, 2022 |
EX-99.1 2 d279078dex991.htm EX-99.1 Exhibit 1 JOINT FILING AGREEMENT Each of the undersigned agrees that (i) the statement on Schedule 13G relating to the Class A Common Stock of Bioventus, Inc., has been adopted and filed on behalf of each of them, (ii) all future amendments to such statement on Schedule 13G/A will, unless written notice to the contrary is delivered as described below, be jointly |
|
| January 13, 2022 |
BVS / Bioventus Inc. Class A / INTEGRATED CORE STRATEGIES (US) LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (AMENDMENT NO. 1) BIOVENTUS INC. (Name of Issuer) CLASS A COMMON STOCK, PAR VALUE $0.001 PER SHARE (Title of Class of Securities) 09075A108 (CUSIP Number) DECEMBER 31, 2021 (Date of event which requires filing of this statement) Check the appropriate box to designate the r |
|
| January 12, 2022 |
Bioventus Announces Preliminary Fourth Quarter and Full-Year 2021 Revenue EX-99.1 2 exhibit991preliminaryresul.htm EX-99.1 Exhibit 99.1 Bioventus Announces Preliminary Fourth Quarter and Full-Year 2021 Revenue DURHAM, NC – January 11, 2022 – Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, announced today preliminary revenue results for the fourth quarter and full-year 2021. Preliminary, unaudited revenue fo |
|
| January 12, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 11, 2022 Bioventus Inc. (Exact name of registrant as specified in charter) Delaware 001-37844 81-0980861 (State or other jurisdiction of incorporation) (Commission File Number |
|
| December 27, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 20, 2021 Bioventus Inc. (Exact name of registrant as specified in charter) Delaware 001-37844 81-0980861 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| November 22, 2021 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 17, 2021 Bioventus Inc. (Exact name of registrant as specified in charter) Delaware 001-37844 81-0980861 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| November 22, 2021 |
EX-10.1 2 exhibit101.htm EX-10.1 Exhibit 10.1 LEASE THIS LEASE is entered into as of the 17th day of November 2021 by and between 7101 GOODLETT FARMS PARKWAY, LLC, a Tennessee limited liability company ("Landlord"), with its principal offices at 95 Froelich Farm Blvd., Woodbury, New York 11797, and BIOVENTUS, LLC, a Delaware limited liability company, with its principal place of business at 4721 E |
|
| November 17, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 11, 2021 Bioventus Inc. (Exact name of registrant as specified in charter) Delaware 001-37844 81-0980861 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| November 10, 2021 |
EX-10.1 2 exhibit101-q32021.htm EX-10.1 Exhibit 10.1 AMENDMENT NO. 1 TO CREDIT AND GUARANTY AGREEMENT THIS AMENDMENT NO. 1 TO CREDIT AND GUARANTY AGREEMENT, dated as of August 29, 2021 (this “Amendment”), made by and among BIOVENTUS LLC, a Delaware limited liability company (“Borrower”), the Guarantor Subsidiaries party hereto, the LENDERS party hereto (the “Consenting Lenders”) and WELLS FARGO BA |
|
| November 10, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended October 2, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: |
|
| November 9, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2021 Bioventus Inc. (Exact name of registrant as specified in charter) Delaware 001-37844 81-0980861 (State or other jurisdiction of incorporation) (Commission File Number |
|
| November 9, 2021 |
Bioventus Reports Third Quarter Results; Updates Full-Year 2021 Financial Guidance Exhibit 99.1 Bioventus Reports Third Quarter Results; Updates Full-Year 2021 Financial Guidance DURHAM, NC ? November 9, 2021 ? Bioventus Inc. (Nasdaq: BVS) ("Bioventus" or "the Company"), a global leader in innovations for active healing, today reported financial results for three and nine months ended October 2, 2021. Q3 Financial Summary & Recent Highlights: ?Net Sales of $108.9 million, up $23 |
|
| October 29, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 29, 2021 Bioventus Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37844 81-0980861 (Commission File Nu |
|
| October 29, 2021 |
As filed with the Securities and Exchange Commission on October 29, 2021 As filed with the Securities and Exchange Commission on October 29, 2021 Registration No. |
|
| October 29, 2021 |
Misonix, Inc. 2005 Employee Equity Incentive Plan, as amended Exhibit 99.7 MISONIX, INC. 2005 EMPLOYEE EQUITY INCENTIVE PLAN ARTICLE I PURPOSE AND EFFECTIVENESS 1.1 Purpose. The purpose of the MISONIX, INC. 2005 Employee Equity Incentive Plan (the ?Plan?) is to promote the success of MISONIX, INC. (the ?Company?) by providing a method whereby officers, employees, and independent contractors providing services to the Company and its Affiliates may be encourag |
|
| October 29, 2021 |
Misonix, Inc. 2012 Employee Equity Incentive Plan, as amended EX-99.4 9 d250775dex994.htm EX-99.4 Exhibit 99.4 MISONIX, INC. 2012 Employee Equity Incentive Plan ARTICLE I PURPOSE AND EFFECTIVENESS 1.1 Purpose. The purpose of the MISONIX, INC. 2012 Employee Equity Incentive Plan (the “Plan”) is to promote the success of MISONIX, INC. (the “Company”) by providing a method whereby officers, employees, and independent contractors providing services to the Compan |
|
| October 29, 2021 |
Bioventus Completes the Acquisition of Misonix EX-99.1 3 d248592dex991.htm EX-99.1 Exhibit 99.1 Bioventus 4721 Emperor Blvd., Suite 100 Durham, NC 27703 USA NEWS Bioventus Completes the Acquisition of Misonix DURHAM, NC – October 29, 2021 – Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, has completed the acquisition of Misonix, Inc. (“Misonix”), a provider of minimally invasive t |
|
| October 29, 2021 |
EX-10.1 2 d248592dex101.htm EX-10.1 Exhibit 10.1 EXECUTION VERSION AMENDMENT NO. 2 TO CREDIT AND GUARANTY AGREEMENT THIS AMENDMENT NO. 2 TO CREDIT AND GUARANTY AGREEMENT, dated as of October 29, 2021 (this “Amendment”), made by and among BIOVENTUS LLC, a Delaware limited liability company (“Borrower”), OYSTER MERGER SUB I, INC., a Delaware corporation, OYSTER MERGER SUB II, LLC, a Delaware limited |
|
| October 29, 2021 |
Misonix, Inc. 2009 Non-Employee Director Stock Option Plan, as amended Exhibit 99.5 MISONIX, INC. 2009 NON-EMPLOYEE DIRECTOR STOCK OPTION PLAN 1. GENERAL 1.1 Purpose of the Plan The purpose of the MISONIX, INC. 2009 Non-Employee Director Stock Option Plan (the ?Plan?) is to enable MISONIX, INC. (the ?Company?) to attract and retain persons of exceptional ability to serve as directors of the Company and to align the interests of directors and shareholders in enhancing |
|
| October 29, 2021 |
Misonix, Inc. 2009 Employee Equity Incentive Plan, as amended EX-99.6 11 d250775dex996.htm EX-99.6 Exhibit 99.6 MISONIX, INC. 2009 Employee Equity Incentive Plan ARTICLE I PURPOSE AND EFFECTIVENESS 1.1 Purpose. The purpose of the MISONIX, INC. 2009 Employee Equity Incentive Plan (the “Plan”) is to promote the success of MISONIX, INC. (the “Company”) by providing a method whereby officers, employees, and independent contractors providing services to the Compa |
|
| October 29, 2021 |
Misonix, Inc. 2012 Non-Employee Director Stock Option Plan, as amended EX-99.3 8 d250775dex993.htm EX-99.3 Exhibit 99.3 MISONIX, INC. 2012 NON-EMPLOYEE DIRECTOR STOCK OPTION PLAN 1. GENERAL 1.1 Purpose of the Plan The purpose of the MISONIX, INC. 2012 Non-Employee Director Stock Option Plan (the “Plan”) is to enable MISONIX, INC. (the “Company”) to attract and retain persons of exceptional ability to serve as directors of the Company and to align the interests of dir |
|
| October 29, 2021 |
Misonix, Inc. 2014 Employee Equity Incentive Plan, as amended EX-99.2 7 d250775dex992.htm EX-99.2 Exhibit 99.2 MISONIX, INC. 2014 Employee Equity Incentive Plan ARTICLE I PURPOSE AND EFFECTIVENESS 1.1 Purpose. The purpose of the MISONIX, INC. 2014 Employee Equity Incentive Plan (the “Plan”) is to promote the success of MISONIX, INC. (the “Company”) by providing a method whereby officers, employees, and independent contractors providing services to the Compan |
|
| October 29, 2021 |
Misonix, Inc. 2017 Equity Incentive Plan, as amended EX-99.1 6 d250775dex991.htm EX-99.1 Exhibit 99.1 MISONIX, INC. 2017 EQUITY INCENTIVE PLAN Section 1. Purpose. The purposes of this Misonix, Inc. 2017 Equity Incentive Plan (the “Plan”) are (1) to make available to key employees, directors and consultants certain compensatory arrangements related to the growth in value of the common stock of the Company so as to generate an increased incentive to c |
|
| October 26, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 26, 2021 Bioventus Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37844 81-0980861 (Commission File Nu |
|
| October 26, 2021 |
Bioventus and Misonix Stockholders Approve the Acquisition of Misonix by Bioventus EX-99.1 2 d228268dex991.htm EX-99.1 Exhibit 99.1 Bioventus and Misonix Stockholders Approve the Acquisition of Misonix by Bioventus DURHAM, NC and FARMINGDALE, NY – October 26, 2021 – Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, and Misonix, Inc. (Nasdaq: MSON) (“Misonix”), a provider of minimally invasive therapeutic ultrasonic te |
|
| October 18, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 18, 2021 BIOVENTUS INC. (Exact name of Registrant as specified in its charter) Delaware 001-37844 81-0980861 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| October 18, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 18, 2021 BIOVENTUS INC. (Exact name of Registrant as specified in its charter) Delaware 001-37844 81-0980861 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| September 24, 2021 |
MERGER PROPOSAL—YOUR VOTE IS VERY IMPORTANT Table of Contents Filed pursuant to Rule 424(b)(3) Registration No. 333-259392 MERGER PROPOSAL?YOUR VOTE IS VERY IMPORTANT Dear Bioventus Stockholders and Misonix Stockholders: On July 29, 2021, Bioventus Inc., which is referred to as ?Bioventus,? Oyster Merger Sub I, Inc., a wholly owned subsidiary of Bioventus, which is referred to as ?Merger Sub I,? Oyster Merger Sub II, LLC, a wholly owned sub |
|
| September 22, 2021 |
Consent of J.P. Morgan Securities LLC. Exhibit 99.2 CONSENT OF J.P. MORGAN SECURITIES LLC We hereby consent to (i) the inclusion of our opinion letter dated July 29, 2021 to the Board of Directors of Misonix, Inc. (the ?Company?) included in Annex C to the Joint Proxy Statement/Prospectus relating to the proposed merger of the Company and Bioventus Inc., and (ii) the references to such opinion in such Joint Proxy Statement/Prospectus. |
|
| September 22, 2021 |
BIOVENTUS INC. 4721 Emperor Boulevard, Suite 400 Durham, North Carolina 27703 BIOVENTUS INC. 4721 Emperor Boulevard, Suite 400 Durham, North Carolina 27703 September 22, 2021 VIA EDGAR Division of Corporation Finance Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attention: Mr. Chris Edwards Re: Bioventus Inc. Registration Statement on Form S-4 (File No. 333-259392) Ladies and Gentlemen: Pursuant to Rule 461 promulgated under the Securities Act |
|
| September 22, 2021 |
Table of Contents As filed with the U.S. Securities and Exchange Commission on September 22, 2021 Registration No. 333-259392 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 to FORM S-4 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 BIOVENTUS INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 3841 94-0980861 (State of Incorporation |
|
| September 22, 2021 |
Consent of Perella Weinberg Partners LLC. Exhibit 99.1 Consent of Perella Weinberg Partners LP We hereby consent to the use in Amendment No. 1 to the Registration Statement of Bioventus Inc. on Form S-4 and in the Joint Proxy Statement/Prospectus of Bioventus Inc. and Misonix, Inc., which is part of the Registration Statement, filed on September 8, 2021 (the “Registration Statement”), of our opinion dated July 29, 2021 appearing as Annex |
|
| September 8, 2021 |
Consent of Patrick Beyer, to be named as director. Exhibit 99.4 Consent to Reference in Joint Proxy Statement/Prospectus Bioventus Inc. (the “Company”) is filing a Registration Statement on Form S-4 with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”). In connection therewith, I hereby consent, pursuant to Rule 438 of the Securities Act, to the reference to me in the joint proxy statement/ |
|
| September 8, 2021 |
Consent of Perella Weinberg Partners LLC. Exhibit 99.1 Consent of Perella Weinberg Partners LP We hereby consent to the use in the Registration Statement of Bioventus Inc. on Form S-4 and in the Joint Proxy Statement/Prospectus of Bioventus Inc. and Misonix, Inc., which is part of the Registration Statement, filed on September 8, 2021 (the “Registration Statement”), of our opinion dated July 29, 2021 appearing as Annex B to such Joint Pro |
|
| September 8, 2021 |
As filed with the U.S. Securities and Exchange Commission on September 8, 2021 Table of Contents As filed with the U.S. Securities and Exchange Commission on September 8, 2021 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-4 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 BIOVENTUS INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 3841 94-0980861 (State of Incorporation) (Primary Standard Indust |
|
| September 8, 2021 |
Form of Proxy Card for Special Meeting of Misonix, Inc. Exhibit 99.6 YOUR VOTE IS IMPORTANT. PLEASE VOTE TODAY. Vote by Internet - QUICK EASY IMMEDIATE - 24 Hours a Day, 7 Days a Week or by Mail MISONIX, INC. Your Internet vote authorizes the named proxies to vote your shares in the same manner as if you marked, signed and returned your proxy card. Votes submitted electronically over the Internet must be received by [ ] Eastern Time, on [ ], 2021. INTE |
|
| September 8, 2021 |
Consent of Stavros Vizirgianakis, to be named as director. Exhibit 99.3 Consent to Reference in Joint Proxy Statement/Prospectus Bioventus Inc. (the ?Company?) is filing a Registration Statement on Form S-4 with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the ?Securities Act?). In connection therewith, I hereby consent, pursuant to Rule 438 of the Securities Act, to the reference to me in the joint proxy statement/ |
|
| September 8, 2021 |
Consent of J.P. Morgan Securities LLC. Exhibit 99.2 CONSENT OF J.P. MORGAN SECURITIES LLC We hereby consent to (i) the inclusion of our opinion letter dated July 29, 2021 to the Board of Directors of Misonix, Inc. (the “Company”) included in Annex C to the Joint Proxy Statement/Prospectus relating to the proposed merger of the Company and Bioventus Inc., and (ii) the references to such opinion in such Joint Proxy Statement/Prospectus. |
|
| September 8, 2021 |
Form of Proxy Card for Special Meeting of Bioventus Inc. Exhibit 99.5 BIOVENTUS INC. [TBD] VOTE BY INTERNET Before The Meeting - Go to www.proxyvote.com Use the Internet to transmit your voting instructions and for electronic delivery of information up until 11:59 p.m. Eastern Time the day before the cut-off date or meeting date. Have your proxy card in hand when you access the web site and follow the instructions to obtain your records and to create an |
|
| August 30, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 30, 2021 Bioventus Inc. (Exact name of registrant as specified in charter) Delaware 001-37844 81-0980861 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| August 25, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 25, 2021 Bioventus Inc. (Exact name of registrant as specified in charter) Delaware 001-37844 81-0980861 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| August 11, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended July 3, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001 |
|
| August 10, 2021 |
Bioventus Reports Second Quarter Results; Updates Full Year 2021 Financial Guidance EX-99.1 2 bioventusex-991q22021.htm EX-99.1 Exhibit 99.1 Bioventus Reports Second Quarter Results; Updates Full Year 2021 Financial Guidance DURHAM, NC – August 10, 2021 – Bioventus Inc. (Nasdaq: BVS) ("Bioventus" or "the Company"), a global leader in innovations for active healing, today reported financial results for three and six months ended July 3, 2021. Q2 Financial Summary & Recent Highligh |
|
| August 10, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 10, 2021 Bioventus Inc. (Exact name of registrant as specified in charter) Delaware 001-37844 81-0980861 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| July 30, 2021 |
Bioventus LLC (Update) July 29, 2021 Filed by Bioventus Inc. Pursuant to Rule 425 Under the Securities Act of 1933 And Deemed Filed Pursuant to Rule 14a-12 Under the Securities Exchange Act of 1934 Subject Company: Misonix, Inc. Commission File No. 001-10986 This filing relates to the proposed acquisition of Misonix, Inc., a Delaware corporation (?Misonix?) by Bioventus Inc., a Delaware corporation (?Bioventus?), pursuant to the term |
|
| July 29, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 29, 2021 Bioventus Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37844 81-0980861 (Commission File Numbe |
|
| July 29, 2021 |
EX-99.1 2 exhibit991preliminaryresul.htm EX-99.1 Bioventus Inc. Reports Preliminary Second Quarter Net Sales; Updates Full-Year 2021 Net Sales Guidance DURHAM, NC – July 29, 2021 – Bioventus Inc. (Nasdaq: BVS) ("Bioventus" or "the Company"), a global leader in innovations for active healing, today reported preliminary financial results for the three months ended July 3, 2021. Preliminary Second Qu |
|
| July 29, 2021 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 29, 2021 Bioventus Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37844 81-0980861 (Commission File Numbe |
|
| July 29, 2021 |
EX-99.3 5 d155859dex993.htm EX-99.3 Exhibit 99.3 FORM OF LOCK-UP AGREEMENT July 29, 2021 Bioventus Inc. 4721 Emperor Boulevard, Suite 100 Durham, North Carolina 27703 Re: BIOVENTUS INC. Ladies and Gentlemen: The undersigned understands that, concurrently with this agreement (the “Letter Agreement”), Bioventus Inc., a Delaware corporation (“Parent”), is entering into an Agreement and Plan of Merger |
|
| July 29, 2021 |
EX-99.2 4 d155859dex992.htm EX-99.2 Exhibit 99.2 Execution Version VOTING AND SUPPORT AGREEMENT This VOTING AND SUPPORT AGREEMENT (this “Agreement”) is entered into as of July 29, 2021, by and between Misonix, Inc., a Delaware corporation (the “Company”), and the persons set forth on Schedule A attached hereto (each, a “Stockholder” and, collectively, the “Stockholders”). Capitalized terms used bu |
|
| July 29, 2021 |
EX-2.1 2 d155859dex21.htm EX-2.1 Exhibit 2.1 AGREEMENT AND PLAN OF MERGER by and among: BIOVENTUS INC., a Delaware corporation; OYSTER MERGER SUB I, INC., a Delaware corporation; OYSTER MERGER SUB II, LLC, a Delaware limited liability company; and MISONIX, INC. a Delaware corporation Dated as of July 29, 2021 TABLE OF CONTENTS Page ARTICLE I. THE MERGERS 2 Section 1.1 The Mergers; Effect of Merger |
|
| July 29, 2021 |
425 1 d179838d425.htm 425 Filed by Bioventus Inc. Pursuant to Rule 425 Under the Securities Act of 1933 And Deemed Filed Pursuant to Rule 14a-12 Under the Securities Exchange Act of 1934 Subject Company: Misonix, Inc. Commission File No. 001-10986 This filing relates to the proposed acquisition of Misonix, Inc., a Delaware corporation (“Misonix”) by Bioventus Inc., a Delaware corporation (“Biovent |
|
| July 29, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 29, 2021 Bioventus Inc. (Exact name of registrant as specified in charter) Delaware 001-37844 81-0980861 (State or other jurisdiction of incorporation) (Commission File Number) ( |
|
| July 29, 2021 |
EX-99.1 3 d155859dex991.htm EX-99.1 Exhibit 99.1 Execution Version VOTING AND SUPPORT AGREEMENT This VOTING AND SUPPORT AGREEMENT (this “Agreement”) is entered into as of July 29, 2021, by and between Bioventus Inc., a Delaware corporation (“Parent”), and the persons set forth on Schedule A attached hereto (each, a “Stockholder” and, collectively, the “Stockholders”). Capitalized terms used but no |
|
| July 29, 2021 |
Filed by Bioventus Inc. Pursuant to Rule 425 Under the Securities Act of 1933 And Deemed Filed Pursuant to Rule 14a-12 Under the Securities Exchange Act of 1934 Subject Company: Misonix, Inc. Commission File No. 001-10986 This filing relates to the proposed acquisition of Misonix, Inc., a Delaware corporation (?Misonix?) by Bioventus Inc., a Delaware corporation (?Bioventus?), pursuant to the term |
|
| July 14, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 14, 2021 Bioventus Inc. (Exact name of registrant as specified in charter) Delaware 001-37844 81-0980861 (State or other jurisdiction of incorporation) (Commission File Number) ( |
|
| May 13, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Mark One ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended April 3, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001- |
|
| May 12, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2021 Bioventus Inc. (Exact name of registrant as specified in charter) Delaware 001-37844 81-0980861 (State or other jurisdiction of incorporation) (Commission File Number) (I |
|
| May 12, 2021 |
Bioventus Inc. Reports First Quarter Results; Updates Full Year 2021 Financial Guidance EX-99.1 2 bioventusex-991.htm EX-99.1 Exhibit 99.1 Bioventus Inc. Reports First Quarter Results; Updates Full Year 2021 Financial Guidance DURHAM, NC – May 12, 2021 – Bioventus Inc. (Nasdaq: BVS) ("Bioventus" or "the Company"), a global leader in innovations for active healing, today reported financial results for three months ended April 3, 2021. This press release presents historical results, fo |
|
| March 31, 2021 |
Bioventus Acquires Bioness, Inc. EX-99.1 Exhibit 99.1 Bioventus 4721 Emperor Blvd., Suite 100 Durham, NC 27703 USA NEWS Bioventus Acquires Bioness, Inc. DURHAM, NC – March 30, 2021 – Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, has acquired Bioness, Inc. (“Bioness”), a global leader in neuromodulation and rehabilitation medical devices through its innovative perip |
